Bovalto Ibraxion (inactivated IBR virus) - QI02AA03
Updated on site: 08-Feb-2018
|Nafn lyfs:||Bovalto Ibraxion|
|Efni:||inactivated IBR virus|
Bovine rhinotracheitis vaccine (inactivated)
This is a summary of the European public assessment report (EPAR) for Bovalto Ibraxion. It explains how the Agency assessed this veterinary medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Bovalto Ibraxion.
For practical information about using Bovalto Ibraxion, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
What is Bovalto Ibraxion and what is it used for?
Bovalto Ibraxion is a veterinary vaccine used to protect cattle against infectious bovine rhinotracheitis (IBR) virus. IBR virus infections affect the airways with nasal discharge, conjunctivitis (inflammation of the eye) and coughing.
Bovalto Ibraxion contains the active substance inactivated gene deleted IBR virus.
How is Bovalto Ibraxion used?
Bovalto Ibraxion is available as an emulsion and can only be obtained with a prescription. The vaccine is given into the neck at the front of the shoulder. Two injections are given 3 weeks apart to calves from age 2 weeks provided they have not acquired antibodies against IBR virus from the mother. When there are antibodies the vaccine should be given to calves from age 3 months. A booster injection is given at 6 month intervals.